Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients

Breast Cancer

Volumn 17, Issue 3, 2010, Pages 212-217

  Sagara, Yasuaki ^a   Kosha, Shoichiro ^b   Baba, Shinichi ^a   Dokiya, Fumiko ^a   Tamada, Shugo ^a   Sagara, Yoshiaki ^a   Matsuyama, Yoshito ^a   Ohi, Yasuyo ^a   Ando, Mitsutake ^a   Rai, Yoshiaki ^a   Sagara, Yoshiatsu ^a   Douchi, Tsutomu ^b  

^a SAGARA HOSPITAL   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Anastrozole; Aromatase inhibitor; Bone mineral density; Breast cancer; Fracture

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE MINERAL; BRAIN INFARCTION; BRAIN ISCHEMIA; BREAST CANCER; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FRACTURE; HEART INFARCTION; HOT FLUSH; HUMAN; JAPANESE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MUSCULOSKELETAL DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; RASH; SIDE EFFECT; TREATMENT DURATION; VAGINAL DRYNESS; AGED; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; INCIDENCE; JAPAN; MIDDLE AGED; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; ARTHRALGIA; BONE DENSITY; BREAST NEOPLASMS; CEREBRAL INFARCTION; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; INCIDENCE; JAPAN; MIDDLE AGED; NITRILES; POSTMENOPAUSE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TRIAZOLES;

EID: 77955516183     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-009-0135-7     Document Type: Article

References (32)

1. EV McCloskey RA Hannon G Lakner WD Fraser G Clack A Miyamoto, et al. 2007 Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women Eur J Cancer 43 17 2523 2531 10.1016/j.ejca.2007.08.029 1:CAS:528:DC%2BD2sXhtlWrsb3E 18029171 (Pubitemid 350086940)
2. AH Paterson 2005 Evaluating bone mass and bone quality in patients with breast cancer Clin Breast Cancer 5 Suppl 2 S41 S45 10.3816/CBC.2005.s.003 15807923
3. R Eastell JE Adams RE Coleman A Howell RA Hannon J Cuzick, et al. 2008 Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230 J Clin Oncol 26 7 1051 1057 10.1200/JCO.2007.11.0726 1:CAS:528:DC%2BD1cXktVKisbo%3D 18309940
4. RL Theriault 2005 Strategies to prevent chemotherapy-induced bone loss in women with breast cancer Clin Breast Cancer 5 Suppl 2 S63 S70 10.3816/CBC.2005.s.006 15807926
5. PE Lonning J Geisler LE Krag B Erikstein Y Bremnes AI Hagen, et al. 2005 Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer J Clin Oncol 23 22 5126 5137 10.1200/JCO.2005.07.097 15983390 (Pubitemid 46224021)
6. RT Chlebowski 2005 Bone health in women with early-stage breast cancer Clin Breast Cancer 5 Suppl 2 S35 S40 10.3816/CBC.2005.s.002 15807922
7. RE Coleman 2004 Hormone- and chemotherapy-induced bone loss in breast cancer Oncology (Williston Park) 18 5 Suppl 3 16 20
8. T Douchi S Kosha R Kan S Nakamura T Oki Y Nagata 1997 Predictors of bone mineral loss in patients with ovarian cancer treated with anticancer agents Obstet Gynecol 90 1 12 15 10.1016/S0029-7844(97)00124-5 1:STN:280: DyaK2szltFGhsA%3D%3D 9207804 (Pubitemid 27272947)
9. WR Miller JM Dixon 2000 Antiaromatase agents: preclinical data and neoadjuvant therapy Clin Breast Cancer 1 Suppl 1 S9 S14 10.3816/CBC.2000.s.002 1:STN:280:DC%2BD383jtFOhuw%3D%3D 11970756
10. DC Johannessen T Engan E Di Salle MG Zurlo J Paolini G Ornati, et al. 1997 Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study Clin Cancer Res 3 7 1101 1108 1:CAS:528:DyaK2sXkvFCgsLw%3D 9815789
11. M Baum A Buzdar J Cuzick J Forbes J Houghton A Howell, et al. 2003 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer 98 9 1802 1810 10.1002/cncr.11745 1:CAS:528:DC%2BD3sXpt1arsbc%3D 14584060 (Pubitemid 37310221)
12. AU Buzdar 2004 The ATAC (Arimidex, Tamoxifen, alone or in combination) trial: an update Clin Breast Cancer 5 Suppl 1 S6 S12 10.3816/CBC.2004.s.008 15347433
13. A Brufsky 2006 Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update Semin Oncol 33 2 Suppl 7 S13 S17 10.1053/j.seminoncol.2006.03.022 1:CAS:528:DC%2BD28XmsVahtrw%3D 16730272 (Pubitemid 43765637)
14. RE Coleman LM Banks SI Girgis LS Kilburn E Vrdoljak J Fox, et al. 2007 Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study Lancet Oncol 8 2 119 127 10.1016/S1470-2045(07)70003-7 1:CAS:528:DC%2BD2sXhtlSgt7c%3D 17267326 (Pubitemid 46158372)
15. AU Buzdar RC Coombes PE Goss EP Winer 2008 Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer Cancer 112 3 Suppl 700 709 10.1002/cncr.23193 1:CAS:528:DC%2BD1cXis1Wjsbs%3D 18072256 (Pubitemid 351186392)
16. Y Yonehara I Iwamoto S Kosha Y Rai Y Sagara T Douchi 2007 Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients J Obstet Gynaecol Res 33 5 696 699 10.1111/j.1447-0756.2007.00634.x 1:CAS:528:DC%2BD2sXht1CnsL%2FM 17845332 (Pubitemid 47383626)
17. P Hadji 2007 Reducing the risk of bone loss associated with breast cancer treatment Breast 16 Suppl 3 S10 S15 10.1016/j.breast.2007.10.004 1:STN:280:DC%2BD1c%2Fpt1yktA%3D%3D 18023583
18. MF Gnant B Mlineritsch G Luschin-Ebengreuth S Grampp H Kaessmann M Schmid, et al. 2007 Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group J Clin Oncol 25 7 820 828 10.1200/JCO.2005.02.7102 1:CAS:528:DC%2BD2sXjvVKmtLw%3D 17159195 (Pubitemid 350002882)
19. HA Harvey 2004 Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy Semin Oncol 31 6 Suppl 12 23 30 10.1053/j. seminoncol.2004.09.023 1:CAS:528:DC%2BD2MXit1Gksbs%3D 15719598 (Pubitemid 40616921)
20. MS Aapro 2004 Long-term implications of bone loss in breast cancer Breast 13 Suppl 1 S29 S37 10.1016/j.breast.2004.09.005 15585380 (Pubitemid 39654741)
21. HL Judd IM Shamonki AM Frumar LD Lagasse 1982 Origin of serum estradiol in postmenopausal women Obstet Gynecol 59 6 680 686 1:CAS:528:DyaL38XkvVGnu7s%3D 7078905
22. A Howell J Cuzick M Baum A Buzdar M Dowsett JF Forbes, et al. 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 9453 60 62 10.1016/S0140-6736(04)17666-6 1:STN:280:DC%2BD2M%2FhsVartA%3D%3D 15639680 (Pubitemid 40082147)
23. B Thurlimann A Keshaviah AS Coates H Mouridsen L Mauriac JF Forbes, et al. 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 26 2747 2757 10.1056/NEJMoa052258 16382061 (Pubitemid 43016814)
24. JF Forbes J Cuzick A Buzdar A Howell JS Tobias M Baum 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 1 45 53 10.1016/S1470- 2045(07)70385-6 18083636
25. MC Wang M Aguirre GS Bhudhikanok CG Kendall S Kirsch R Marcus, et al. 1997 Bone mass and hip axis length in healthy Asian, black, Hispanic, and white American youths J Bone Miner Res 12 11 1922 1935 10.1359/jbmr.1997.12.11.1922 1:STN:280:DyaK1c%2FksV2mtg%3D%3D 9383697
26. E Barrett-Connor ES Siris LE Wehren PD Miller TA Abbott ML Berger, et al. 2005 Osteoporosis and fracture risk in women of different ethnic groups J Bone Miner Res 20 2 185 194 10.1359/JBMR.041007 15647811
27. T Douchi S Yamamoto T Oki K Maruta R Kuwahata H Yamasaki, et al. 2000 The effects of physical exercise on body fat distribution and bone mineral density in postmenopausal women Maturitas 35 1 25 30 10.1016/S0378-5122(00)00094-3 1:STN:280:DC%2BD3c3msVSisA%3D%3D 10802396 (Pubitemid 30236277)
28. BE Hillner JN Ingle RT Chlebowski J Gralow GC Yee NA Janjan, et al. 2003 American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 21 4042 4057 10.1200/JCO.2003.08.017 1:CAS:528:DC%2BD2cXpsVajsbY%3D 12963702 (Pubitemid 46606220)
29. EA Perez 2007 Safety of aromatase inhibitors in the adjuvant setting Breast Cancer Res Treat 105 Suppl 1 75 89 10.1007/s10549-007-9704-7 17912638 (Pubitemid 47524804)
30. KM Rexrode CH Hennekens WC Willett GA Colditz MJ Stampfer JW Rich-Edwards, et al. 1997 A prospective study of body mass index, weight change, and risk of stroke in women JAMA 277 19 1539 1545 10.1001/jama.277.19.1539 1:STN:280:DyaK2s3pslOgtA%3D%3D 9153368
31. R Eastell RA Hannon J Cuzick M Dowsett G Clack JE Adams 2006 Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230) J Bone Miner Res 21 8 1215 1223 10.1359/jbmr.060508 1:CAS:528:DC%2BD28XotlKrsL8%3D 16869719 (Pubitemid 44128334)
32. LJ Scott SJ Keam 2006 Letrozole: in postmenopausal hormone-responsive early-stage breast cancer Drugs 66 3 353 362 10.2165/00003495-200666030-00010 1:CAS:528:DC%2BD28XjslOktb4%3D 16526826 (Pubitemid 46291773)